Oct 28, 2021 / 11:30AM GMT
Mark Christopher Griffiths - Dishman Carbogen Amcis Limited - Global CEO & Director
So good afternoon, everybody. We, at Dishman Carbogen Amcis Limited, hope you and all your family are safe and well. I'm going to give a short introduction, and then I'll hand over to Harshil Dalal, our CFO.
So we've had a solid performance this quarter. The key highlights are a successful completion of an FDA audit for a confidential client's launch in November '21 of the lung cancer indication at one of our Swiss sites. That follows on from a successful paper audit by the FDA early on in the year.
We continue to have excellent progress on the rebirth of our Bavla location in India, and we have continued to supply customers with product, and we continued to open new facilities, reopen facilities and bring our products back on to line. The construction of our new commercial facility for formulation in France is on target, and the facility looks fantastic, and we're really, really looking forward to that. Marketing efforts have already commenced.
The commercial pipeline remains very strong,
Q2 2022 Dishman Carbogen Amcis Ltd Earnings Call Transcript
Mar 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers